English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases.

MPS-Authors
/persons/resource/persons80597

Wollweber,  Bastian
Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80390

Keck,  Martin E.
Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

/persons/resource/persons80515

Schmidt,  Ulrike
Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Wollweber, B., Keck, M. E., & Schmidt, U. (2015). Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases. Therapeutic advances in psychopharmacology, 5(4), 208-13. doi:10.1177/2045125315585652.


Cite as: https://hdl.handle.net/11858/00-001M-0000-002A-0837-5
Abstract
INTRODUCTION: There is no drug treatment for nonsuicidal self-injury (NSSI), a highly prevalent and burdensome symptom of several psychiatric diseases like posttraumatic stress disorder (PTSD), personality disorders, and major depression (MD). METHODS: Here, we present a retrospective series of three patients demonstrating a persistent remission in MD-associated NSSI in response to treatment with antipsychotics possessing marked D1 receptor antagonistic activity. RESULTS: To the best of the authors' knowledge, the case series presented is only the second clinical paper suggesting a role for D1 antagonists in NSSI drug therapy. CONCLUSIONS: Together with previously published data from rodent models, the findings suggest a role for D1 antagonists in NSSI drug therapy and hence for the D1 receptor in NSSI pathogenesis. This conclusion is limited by the facts that the patients presented here received polypharmacy and that the D1 receptor antagonistic antipsychotics suggested here as effective 'anti-auto-aggressants' do not address D1 receptors only but multiple neurotransmitter receptors/systems.